PubMed Health⌕ Search

Biomedical subjects

R Kalish

Publications and source records attributed to R Kalish.

30 records · Page 2Linked to original sources
PubMed1989

A polyclonal CD4+ and CD8+ lymphocytosis in a patient doubly infected with HTLV-I and HIV-1: a clinical and molecular analysis.

HTLV-I is associated with adult T-cell leukemia/lymphoma (ATL) characterized by monoclonal expansions of CD4+ T-lymphocytes. In this report we describe a histologically benign, polyclonal HTLV-I infection in a patient exhibiting both an absolute CD4+ and CD8+ lymphocytosis. Three T-cell lines containing integrated HTLV-I proviral copies established from this patient were initially polyclonal, but with time all grew out the same two clones as determined by analysis of their T-cell antigen receptor beta chain gene rearrangements. The patient subsequently developed pulmonary and nasopharyngeal nodules containing HTLV-I infected cells. Restriction analysis of the patient's HTLV-I provirus revealed no differences from prototype HTLV-I and the tax gene was normally expressed in vivo and in vitro. The patient's T-lymphocytosis and HTLV-I+ pulmonary tract nodules were put into a complete clinical remission by treatment with alkylating agents and steroids. Subsequently, the patient developed a severe immunodeficiency state and expired. Retrospective serologic and gene amplification assays for HIV-1 demonstrated that he had been doubly infected from the time of presentation. Postmortem analysis by polymerase chain reaction revealed the presence of both HTLV-I and HIV-1 in lymphatic tissues and the testes; HIV-1 was also detected in brain tissue.

Acquired Immunodeficiency Syndrome↗
PubMed1988

Enzymatic amplification of HTLV-I viral sequences from peripheral blood mononuclear cells and infected tissues.

Human T-cell lymphotropic virus type I (HTLV-I) and human T-cell lymphotropic virus type II (HTLV-II) have been associated with adult T-cell leukemia/lymphoma (ATL) and a rare T-cell variant of hairy cell leukemia, respectively. Direct detection of viral nucleic acid in peripheral blood lymphocytes (PBLs) and infected tissues in carrier patients and those with chronic disease has proven refractory due to viral transcriptional dormancy and the small number of infected cells present. The investigators report here the successful application of the DNA amplification procedure, termed PCR, to the detection of these human oncoviruses. Judicious selection of specific oligonucleotides for primers and probes provides type-specific and simultaneous detection of these two retroviruses. The ability to amplify and detect highly conserved regions of these medically relevant viruses may facilitate the identification of, as yet, uncharacterized retroviruses.

Base Sequence↗
PubMed1986

Adenocarcinoma of the distal esophagus and gastric cardia. Comparison of results of transhiatal esophagectomy and thoracoabdominal esophagogastrectomy.

Between 1965 and 1984, 72 patients underwent operation for adenocarcinoma of the distal esophagus or gastric cardia. A standard transthoracic esophagogastrectomy and esophagogastrostomy was performed in 43 and a transhiatal esophagectomy without thoracotomy and partial proximal gastrectomy was performed in 29. There was no significant difference between the two groups in age, sex, or TNM tumor staging. The perioperative complication rate was 86% in the esophagogastrectomy patients and 48% in the transhiatal esophagectomy patients (p less than 0.05). Mortality was higher in the esophagogastrectomy group (14%) than in the transhiatal esophagectomy group (7%). Average operative blood loss was greater in the esophagogastrectomy patients (2,510 versus 1,187 ml). Average postoperative hospitalization was longer for the esophagogastrectomy patients (22.2 days versus 12.3 days). Both differences are statistically significant (p less than 0.05). Late results, as evaluated by life-table analysis, showed no significant difference in survival between the two groups of patients. Because the morbidity and mortality rates of transhiatal esophagectomy are as low as or lower than those for esophagogastrectomy, late survival is as good, and palliation is superior (less suture-line tumor recurrence and reflux esophagitis), we believe that transhiatal esophagectomy is the preferred operative approach in patients with adenocarcinoma of the distal esophagus or gastric cardia.

Actuarial Analysis↗
PubMed1983

The effects of tumor facilitating factor of B16 melanoma on the macrophage.

B16 cells produce a tumor facilitating factor (TFF) that increases B16 tumor incidence in mice injected with a small number of B16 cells. TFF was derived from serum-free culture supernatant concentrated on an Amicon PM10 membrane. One milliliter of concentrated material represented the product 10(8) B16 cells during a 6-h incubation. We report data that indicate TFF may act by altering macrophage function. In the nude mouse deficient in T cell, but not macrophage function, the injection of 0.8 ml of TFF facilitated tumor development. Subcutaneous injection of 0.7 ml of TFF induced mouse peritoneal macrophages to spread when removed and plated on glass coverslips. This effect peaked 3 days after injection of TFF and was abrogated by heating the TFF to 70 degrees C for 1 h. The injection of TFF was also able to induce macrophage spreading in nude mice. Injection of viable B16 cells induced spreading, as would be predicted if TFF is produced by B16 cells in vivo. In vitro incubation of peritoneal cells with TFF was also able to induce macrophage spreading. Finally, subcutaneous injection of TFF reduced by 80% the accumulation of peritoneal cells in response to intraperitoneal injection of phytohemagglutinin. We suggest that one mode by which TFF facilitates tumor growth is by reducing the numbers of macrophages chemotaxing to the tumor site.

Animals↗
PubMed1980

Increased incidence of tumor takes to B16 melanoma in C57BL/6J mice injected with B16 products.

The injection of either viable B16 melanoma cells, killed B16 cells, or B16 cell products increased the incidence of melanomas in C57Bl/6J mice inoculated with a threshold dose of B16 cells. In all cases the effect was seen whether the facilitating injection was at a site distant from the challenge inoculum or at the same site. Facilitation was seen with B16 cells and products both from in vivo tumors and from tissue culture. However, cells detached from tissue culture flasks with trypsin no longer had facilitating activity. Facilitating activity was found in concentrated cultured supernatants centrifuged at 100,000 X g for 1.5 hr and dialyzed. No activity was detected in the less than 10,000 mol wt fraction. Facilitation was not associated with a change in the time of tumor appearance nor with enhanced growth of B16 cells in culture.

Animals↗
PubMed1978

Kinetics of cytotoxicity of VM-26 and VP-16-213 on L1210 leukemia and hematopoietic stem cells.

The in vivo effects of VM-26 and VP-16-213 upon hematopoietic stem cells and L1210 leukemia cells were quantitated using the spleen-colony assay technique. The effect of VM-26 on leukemia cells was further quantitated using an endpoint dilution assay. The dose-response curves for leukemic clonogenic cells for both agents when given by iv injection were exponential and biphasic, indicating the existence of two populations. The survival of leukemia cells when VM-26 was administered as a 24-hour infusion was less than that found for equivalent doses administered as single injections. The survival kinetics with respect to time for a low dose (0.02 mg/mouse) and a high dose (0.15 mg/mouse) of VM-26 were similar in that the decrease in survival was rapid, reaching a maximum effect within 4 hours after administration. With the low dose, repopulation of the femoral marrow started immediately, whereas with the high dose, there was a 20-hour delay in repopulation. The data from the increase in lifespan studies were in excellent agreement with the quantitative assays. The dose-response curves for the normal hematopoietic clonogenic cells were also exponential, but these cells were much less sensitive to the agents than were the leukemia cells.

Animals↗
PubMedDate not supplied

In vitro function of granulocyte concentrates following passage through an electromechanical infusion pump.

Six units of granulocytes stored for 18 hours at 20 to 24 degrees C without agitation were passed through an electromechanical infusion device pump system (test) (Abbott) and through a 170-micron filter (control). To determine the effect of needle gauge, a 19 or 23 gauge needle was attached to the end of the pump administration set. After passage through the pump, granulocytes were evaluated for signs of cytolysis and functional loss, red cells for hemolysis, platelets for release of beta-thromboglobulin, and plasma for C3a and C5a complement activation. There was no evidence (mean +/- 1 SD) of hemolysis (less than 1.0 vs. less than 1.0 mg/dl), loss of granulocytes (123 +/- 38 X 10(3)/microliters vs. 118 +/- 29 X 10(3)/microliters), changes in any of several tests of neutrophil function, increased release of beta-thromboglobulin (15.8 +/- 5.8 vs. 17.0 +/- 6.6%), or C3a complement activation (483 +/- 221 vs. 500 +/- 200 ng/ml) after passage through the pump system (p greater than 0.05). No significant differences were seen between the use of a 19 or 23 gauge needle. Based on these in vitro data, we conclude that this pump system is acceptable for use in clinical practice when control over rate and volume of granulocyte administration is important.

Cell Survival↗